Company profile
GlobeImmune, Inc.
OTC: GBIM · Healthcare · Biotechnology
#680 of 1,418 Healthcare companies by revenue54th-percentile growth
EA Score
——FH —DQ 23GM —SS 20
v0.1 · 25/100 weight · pillars only
↑ return on assets, net margin · ↓ market scale, workforce scale
Methodology →Revenue TTM
$6.2M
Rev growth YoY (TTM)
+8.3%
Net income (FY)
-$2.8M
Employees
2
as of 2026-08-31
Market cap
$575
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.5M$6.5M2015
Net income-$2.8M-$2.8M2015
Operating income-$2.8M-$2.8M2015
Total assets$11.5M$11.5M2015
Liabilities$8.5M$8.5M2015
Equity$3.0M$3.0M2015
Revenue trend
FY2014 – FY2015 · USD
FY14
FY14
FY14
FY15
Revenue by segment
Filed disclosures · FY2015
By product
Research And Development Services100%
By geography
Not disclosed.
The read
What is GlobeImmune, Inc.’s revenue?
GlobeImmune, Inc. booked $6.5M in FY2015 revenue, growing 8.2% year over year — about the middle of the pack among Healthcare companies we track, at a -42.8% net margin.
Peers · Healthcare
Fate Therapeutics, Inc.43DEvommune, Inc.45DEncision Inc.——Kyntra Bio, Inc.60CViveve Medical, Inc.——Korro Bio, Inc.41DNeighbors
Boulder →Key facts
CEODonald Bellgrau
SectorHealthcare
IndustryBiotechnology
HeadquartersLouisville, CO
ExchangeOTC: GBIM
Employees2
IPO date2014-07-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.